Literature DB >> 29433387

Pharmacological Effects of Scutellarin, An Active Component of Genus Scutellaria and Erigeron: A Systematic Review.

Sebastian Chledzik1, Jakub Strawa1, Katarzyna Matuszek1, Jolanta Nazaruk1.   

Abstract

Flavonoid compound scutellarin (Scu) is quite frequently met in the plant kingdom, particularly in the genus Scutellaria (Lamiaceae) and Erigeron (Asteraceae). The extract of the herb of Erigeron breviscapus, containing this component in high amount, has been used for many years in traditional Chinese medicine. In recent years, studies have made great progress on the usefulness of Scu for treating various diseases by testing its mechanism of action. They support the traditional use of Scu rich plant in heart and cerebral ischemia. Scu can potentially be applied in Alzheimer's disease, Helicobacter pylori infection, vascular complications of diabetes and as an inhibitor of certain carcinomas. Various methods were designed to improve its isolation from plant material, solubility, absorption and bioavailability. On the basis of recent studies, it is suggested that Scu could be a promising candidate for new natural drug and deserves particular attention in further research and development.

Entities:  

Keywords:  Flavone Glucuronide; Pharmacokinetic Studies; Review; Scutellarin; Therapeutic Potential

Mesh:

Substances:

Year:  2018        PMID: 29433387     DOI: 10.1142/S0192415X18500167

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  7 in total

1.  Breviscapine alleviates NASH by inhibiting TGF-β-activated kinase 1-dependent signaling.

Authors:  Tian Lan; Shuo Jiang; Jing Zhang; Qiqing Weng; Yang Yu; Haonan Li; Song Tian; Xin Ding; Sha Hu; Yiqi Yang; Weixuan Wang; Lexun Wang; Duosheng Luo; Xue Xiao; Shenghua Piao; Qing Zhu; Xianglu Rong; Jiao Guo
Journal:  Hepatology       Date:  2021-12-19       Impact factor: 17.298

2.  Scutellarein suppresses Aβ-induced memory impairment via inhibition of the NF-κB pathway in vivo and in vitro.

Authors:  Xiao-Wei Huang; Yan Xu; Xin Sui; He Lin; Jia-Ming Xu; Dong Han; Dou-Dan Ye; Guang-Fu Lv; Yue-Xin Liu; Xiao-Bo Qu; Ming-Hua Duan
Journal:  Oncol Lett       Date:  2019-04-18       Impact factor: 2.967

3.  Scutellarin Reduce the Homocysteine Level and Alleviate Liver Injury in Type 2 Diabetes Model.

Authors:  Yiyu Wang; Xiaoming Fan; Biao Fan; Kerong Jiang; Haoxin Zhang; Feng Kang; Hui Su; Danshan Gu; Shude Li; Shaofang Lin
Journal:  Front Pharmacol       Date:  2020-12-11       Impact factor: 5.810

4.  Combined Effects of Methyldopa and Flavonoids on the Expression of Selected Factors Related to Inflammatory Processes and Vascular Diseases in Human Placenta Cells-An In Vitro Study.

Authors:  Anna Bogacz; Przemysław Ł Mikołajczak; Marlena Wolek; Aleksandra Górska; Michał Szulc; Marcin Ożarowski; Radosław Kujawski; Bogusław Czerny; Hubert Wolski; Tomasz M Karpiński; Agnieszka Seremak-Mrozikiewicz
Journal:  Molecules       Date:  2021-02-26       Impact factor: 4.411

5.  Intravenous Administration of Scutellarin Nanoparticles Augments the Protective Effect against Cerebral Ischemia-Reperfusion Injury in Rats.

Authors:  Chang Yang; Qing Zhao; Shanshan Yang; Libin Wang; Xingyuan Xu; Lisu Li; Wafa T Al-Jamal
Journal:  Mol Pharm       Date:  2022-04-20       Impact factor: 5.364

6.  Scutellarin Ameliorates Renal Injury via Increasing CCN1 Expression and Suppressing NLRP3 Inflammasome Activation in Hyperuricemic Mice.

Authors:  Guozheng Li; Chen Guan; Lingyu Xu; Lin Wang; Chengyu Yang; Long Zhao; Bin Zhou; Congjuan Luo; Hong Luan; Wei Jiang; Chenyu Li; Yan Xu
Journal:  Front Pharmacol       Date:  2020-10-22       Impact factor: 5.810

7.  Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism.

Authors:  Xinran Wang; Cai Zhang; Ning Han; Juyuan Luo; Shuofeng Zhang; Chunguo Wang; Zhanhong Jia; Shouying Du
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.